The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.

[1]  T. Ivanova,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2016 .

[2]  Emily C. O'Brien,et al.  Untangling the paradox: Obesity as prognostic marker in prevalent cardiovascular disease. , 2016, American heart journal.

[3]  L. Räber,et al.  Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. , 2015, European heart journal.

[4]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[5]  D. Wald,et al.  Prevalence of DNA-confirmed familial hypercholesterolaemia in young patients with myocardial infarction. , 2015, European journal of internal medicine.

[6]  J. Kastrup,et al.  Short- and long-term cause of death in patients treated with primary PCI for STEMI. , 2014, Journal of the American College of Cardiology.

[7]  J. Kastelein,et al.  Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. , 2014, Atherosclerosis.

[8]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[9]  G. Watts,et al.  Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.

[10]  B. Nordestgaard,et al.  Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids. , 2012, Danish medical journal.

[11]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[12]  E. Stein,et al.  Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. , 2011, The American journal of cardiology.

[13]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[14]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[15]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[16]  J. Witteman,et al.  Efficacy of statins in familial hypercholesterolaemia: a long term cohort study , 2008, BMJ : British Medical Journal.

[17]  S. Humphries,et al.  Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study , 2008, European heart journal.

[18]  O. Faergeman,et al.  The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. , 2005, Atherosclerosis.

[19]  Carolyn M Hutter,et al.  Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. , 2004, American journal of epidemiology.

[20]  S. Humphries,et al.  Familial hypercholesterolemia and coronary heart disease: a HuGE association review. , 2004, American journal of epidemiology.

[21]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[22]  S. Humphries,et al.  A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. , 2003, Atherosclerosis.